<DOC>
	<DOCNO>NCT00965653</DOCNO>
	<brief_summary>This open-label randomize 2arm study investigate pharmacokinetics , pharmacodynamics , efficacy safety subcutaneously administer tocilizumab patient rheumatoid arthritis show inadequate response methotrexate . Patients randomize receive tocilizumab 162 mg sc either weekly every week , combination methotrexate , 12 week . Assessments make regular interval treatment 3 week follow-up.Target sample size &lt; 50 individual .</brief_summary>
	<brief_title>A Study Subcutaneously Administered Tocilizumab Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>adult 18 75 year age active rheumatoid arthritis &gt; /= 6 month duration inadequate response least 12 week methotrexate , last 8 prior baseline stable dose swell joint count ( SJC ) &gt; /=4 , tender joint count ( TJC ) &gt; /=6 screen baseline DMARDs antiTNFs , methotrexate , withdrawn prior baseline oral corticosteroid ( &lt; /= 10mg/day prednisone equivalent ) NSAIDS stable dose &lt; /= 4 week prior baseline rheumatic autoimmune disease rheumatoid arthritis prior history current inflammatory joint disease rheumatoid arthritis major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow enrollment functional class IV ACR classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>